- Home
- MIRM vs LKQ Comparison
MIRM vs LKQ Comparison
Compare MIRM & LKQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | LKQ |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Motor Vehicles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.0B |
| IPO Year | 2019 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MIRM | LKQ |
|---|---|---|
| Price | $89.69 | $23.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $119.85 | $42.33 |
| AVG Volume (30 Days) | 504.0K | ★ 2.9M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.91% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 0.84 |
| Revenue | $19,138,000.00 | ★ $13,651,000,000.00 |
| Revenue This Year | $26.22 | $2.18 |
| Revenue Next Year | $22.04 | $1.71 |
| P/E Ratio | ★ N/A | $27.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.23 | $21.17 |
| 52 Week High | $130.00 | $37.13 |
Technical Indicators
Market Signals| Indicator | MIRM | LKQ |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 42.51 |
| Support Level | $88.08 | $21.17 |
| Resistance Level | $98.03 | $26.77 |
| Average True Range (ATR) | 3.98 | 0.71 |
| MACD | -0.60 | -0.06 |
| Stochastic Oscillator | 14.55 | 29.66 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About LKQ LKQ Corporation
LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.